瑞士诺华地拉罗司在国内买的到吗？

Is Swiss Novartis deferasirox available in China? Novartis of Switzerland has launched it in the country in 2010, so it can be purchased in China.

Deferasirox, produced by Novartis in Switzerland, was granted orphan drug status by the FDA in 2005 to Enrig (deferasirox) for the treatment of iron overload in non-transfusion-dependent thalassemia. In 2010, Enrig (deferasirox) dispersible tablets were approved for marketing in China. , is approved for the treatment of chronic iron overload caused by frequent blood transfusions in patients with β-thalassemia aged 2 years and above and chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above. In 2012, Enrig (deferasirox) was approved in the EU for the treatment of chronic iron overload thalassemia in patients aged 6 years and older due to frequent blood transfusions (hematocrit ≥7ml/kg/month). It was also approved for the treatment of chronic iron overload caused by blood transfusions when deferoxamine treatment is contraindicated or insufficient. In Japan, this product is approved for the treatment of iron overload caused by blood transfusion.

Swiss Novartis Deferasirox is a prescription drug. The usage and dosage of Swiss Novartis Deferasirox are accurately selected based on the patient's personal condition, constitution, family genetic history and the ingredients of the drug. Therefore, patients using Swiss Novartis Deferasirox need to be under the guidance of a doctor.

Recommended for patients with iron accumulation, such as those who require long-term blood transfusion (blood transfusion volume up to 100 ml/kg) and serum ferritin exceeds 1000 μg/L; corresponding to body weight, it is initially recommended to take a daily dose of 20 mg/kg. Depending on the improvement of serum ferritin indicators, patients may need to adjust or increase the dose of deferasirox. Generally, the dose will be increased in units of 5 mg/kg or 10 mg/kg, but the total dose should not exceed 30 mg/kg per day.

Recommended related hot articles: /newsDetail/88633.html